AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01043562 — intervention group
Intervention type: OTHER
Intervention: Observation of post-shock intrinsic cardiac rhythm
Description: Prior to each of the three ventricular fibrillation inductions performed as part of the binary search protocol, post-shock pacing was re-programmed using a pre-determined, stepwise protocol that progressively decreased the lower rate limit. For the purpose of this protocol, post-shock pacing was considered necessary if 1) ≥7 ventricular-paced beats or 2) asystole >4 seconds was observed in the first 20 seconds after defibrillation, or if the systolic blood pressure demonstrated a >10% decrease from pre-induction baseline at follow-up measurement 1 minute post-defibrillation. Rescue ventricular pacing via the programmer was available for all subjects.
Study NCT00526565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tapas Acupressure Technique
Description: Practice of the TAT technique involves application of pressure to select acupoints combined with specific mental focus. The TAT pose involves lightly touching the tips of the left thumb and 4th finger to the area 1/8 inch above the inner corner of each eye and the 3rd finger to the point midway between the eyes, about ½ inch above eyebrow level. The right hand is on the back of the head, with the palm cradling the occiput and the thumb just above the hairline. Once in this position, the process is to 1) focus attention on the identified problem or behavior to be changed (e.g., over-eating); 2) focus on a positive thought related to the problem; 3) focus on the thought of healing or clearing the origins of the problem; and 4) focus on an awareness of healing or clearing any storage of the problem, at a cellular, mental, emotional, or energetic level.
Study NCT01772147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium bromide 62.5mcg
Description: Inhalation powder
Study NCT01772147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium bromide 125mcg
Description: Inhalation powder
Study NCT01772147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 250mcg/Salmeterol 50mcg
Description: Inhalation powder
Study NCT00747721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 2 ml ampoule containing 200 micrograms dexmedetomidine for dilution with 48 ml 0/9% sodium chloride injection. Titrated to efficacy.
Study NCT00526565 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social support
Description: The LIFE SS maintenance intervention will consist of a series of professionally facilitated social support groups where the session content is directed by the participants. The contact hours for SS will match those of the TAT intervention. The initial SS group session will orient participants to the basics of weight maintenance, and subsequent sessions will provide opportunities for participants to share experiences and ask questions. Participants may choose to use behavioral tools as desired. In addition to the basic materials about weight loss maintenance used in both maintenance interventions, will we use the materials already used in the weight loss program for the SS group as needed. We will measure adherence by taking attendance at the SS group sessions.
Study NCT00674856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxcinod
Description: 750mg
Study NCT03034473 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Translational Research and multimodal treatment
Description: Blood/biopsy samples (tumor \& mucosa) are taken pretherapeutically. Blood samples (serum \& plasma) are drawn at 11 time points during RCTx (e.g. for analysis of 5-FU metabolism, genomic DNA extraction). After pathohistological workup of the TME specimen, the formalin-fixed material will be transferred to the central biobank of KFO179. Blood samples (plasma \& serum) will be drawn during 5y-follow-up. Treatment (based on CAO/ARO/AIO-94- and CAO/ARO/AIO-04-phase-III trials of the GRCSG):~Preoperative RCT: 28x1.8 Gy (total: 50.4 Gy, 5 fractions per week on d1-d38) combined with 5-FU (1000 mg/m2/d) as 120 h civ during 1st and 5th week.~TME-surgery is performed 6 weeks after RCTx. 4 to 8 weeks after surgery, patients receive either 4 cycles 5-FU (500 mg 5-FU/m2 iv, d1-5, repeat d 29-33) or 3 cycles (6 single appl.) of FOLFOX regimen \[(400 mg FA/m2, 2-h civ, d 1; 100 mg oxaliplatin/m2, 2-h civ in 500 ml Glucose 5%, d 1; 2400 mg 5-FU/m2 as 46-h civ) on d1+d15, d30+d45 and d60+d75\].
Study NCT00909714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DC-Stimulator to apply tDCS
Description: Anodal tDCS (20 minutes) stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
Study NCT00909714 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DC-Stimulator to apply Sham tDCS
Description: Sham stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
Study NCT01934075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental health treatment
Description: 6 sessions of individual mental health counseling.
Study NCT01626625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stem cells + hydroxy apatite
Description: patient will be transplanted with stem cells and hydroxyapatite
Study NCT01626625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: autograft taken from iliac crest
Description: patient will be transplanted with autograft
Study NCT03094676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Approximately 12 minutes of massage will be performed in full. The massage will be performed on the lower (anterior) and trunk (posterior)
Study NCT03094676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A wingate protocol will be performed followed by 10 sets of 10 squats followed by jumps.
Study NCT03685292 — intervention group
Intervention type: BEHAVIORAL
Intervention: Behavioral Advisory System
Description: Support and training to help increase throughput while promoting upstanding stature and reproducibility in behavioral testing using cutting edge methodologies.
Study NCT03685292 — intervention group
Intervention type: DRUG
Intervention: Behavioral Treatment
Description: This study addressed the efficacy of cognitive-behavioral therapy (CBT) treatment.
Study NCT03685292 — intervention group
Intervention type: DEVICE
Intervention: Behavioral Division
Description: This study is relative to minimal contact control (MCC).
Study NCT02274064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview and Implementation Intention
Description: Telephone call that includes motivational interviewing techniques and develops an implementation intention plan.
Study NCT04038177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Superset strength training
Description: Three weeks of familiarization (two times per week) to the exercises leg-press, bench press, lateral pulldown and seated rows, followed by superset strength training two days per week for 12-weeks. Superset 1 are bench-press and seated rows, and superset 2 are leg-press and lateral pulldown. Each superset is performed three times.
Study NCT04038177 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional strength training
Description: Three weeks of familiarization (two times per week) to the exercises leg-press, bench press, lateral pulldown and seated rows, followed by strength training two days per week for 12-weeks. Each exercise is performed for three sets with rest intervals between each set.
Study NCT04253431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlucoJect Dual S lancing device (Menarini)
Study NCT04253431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microlet 28G lancets (Bayer)
Study NCT04253431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BGStar Ultra-Thin 33G lancets (Sanofi Aventis)
Study NCT01500213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant
Description: 200 mg PO
Study NCT01500213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Granisetron
Description: 10 mcg/kg IV
Study NCT01500213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: 10 mcg/kg IV
Study NCT01500213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: 20 mg PO and 8 mg PO
Study NCT01500213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg PO and 8 mg PO
Study NCT01500213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (4 X 0 mg capsules) o mg PO
Study NCT00564044 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: excision of the protruding mesh and its surrounding vaginal tissue
Description: A piece of vaginal tissue 12mm\*5mm\*3mm in sized (for control group) and another piece of vaginal tissue combined with protruding mesh of the same size (for study group) will be obtained respectively for each of the two arms during intervention.
Study NCT02306694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advate
Description: Patients who are currently taking Advate as their factor replacement will be eligible for the 5-day study.
Study NCT02099279 — intervention group
Intervention type: DEVICE
Intervention: echocardiography examination
Description: patients underwent echocardiography examination
Study NCT04297852 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vegan drink
Description: Vegan based drink containing vegetables, fruits and plant oils. Dose: 500 mL a day
Study NCT04297852 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo drink Dose: 500 mL a day
Study NCT03897933 — intervention group
Intervention type: PROCEDURE
Intervention: Erector Spinae Plane block ( Group I)
Description: ESP Block was performed preoperative to all patients in ESP block group. Patients in all groups were provided with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
Study NCT03897933 — intervention group
Intervention type: PROCEDURE
Intervention: non- blocked Group (GROUP II)
Description: This group was received no intervetion. Patients in all groups were provided with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
Study NCT03186859 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB) surgery
Description: RYGB operation using surgeons' standard technique
Study NCT03186859 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve Gastrectomy (SG) surgery
Description: SG surgery using surgeons' standard technique
Study NCT02428374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin plus clopidogrel
Description: Crestor 40 mg daily plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo
Study NCT02428374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin plus ticagrelor
Description: Crestor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
Study NCT02428374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin plus clopidogrel
Description: Zocor 40 mg plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo
Study NCT02428374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin plus ticagrelor
Description: Zocor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
Study NCT03744845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: This RCT will utilize an Oculus Go VR headset that delivers VR images and sound. Users will wear the VR headset. A research coordinator will familiarize patients with hardware before use. The VR will be used preoperatively and intraoperatively to distracts patients, and aid with the treatment of pain and anxiety.
Study NCT03199612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: To conduct a randomized placebo controlled study to test the hypothesis that platelet activation and aggregation during ongoing low level hemolysis in outpatients on chronic CF pump support can be reduced by sildenafil.
Study NCT03199612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Negative control to understand the potential changes in platelet activation adn aggregation in comparison to sildenafil.
Study NCT04676685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730
Description: E2730 capsules.
Study NCT04676685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730-matched placebo
Description: E2730-matched placebo capsules.
Study NCT02877719 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Participants were asked to respond to the Chinese version of the Center for Epidemiologic Studies Depression Scale for Children, the Rosenberg self-esteem scale, and the Pediatric Quality of Life Inventory.
Study NCT00793546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: 300 mg =(3x100mg) tablets once daily during the active phase of treatment until disease progression, unacceptable toxicity or withdrawal of consent occurs
Study NCT00793546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: 25 mg tablet once daily
Study NCT00793546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: 25 mg - 1 tablet per day- once daily daily during the active phase of treatment until disease progression, unacceptable toxicity or withdrawal of consent occurs
Study NCT05481268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping Group
Description: In the Kinesiotaping Group patients had muscle technique-inhibition method. An 'I' shaped tape was used for both SCM and upper trapezius. The tension of the tape was adjusted between 20 and 25% and the application was performed in the longest position of the muscle. The inhibition technique was applied from the insertion to the origin of the muscle. The tape was applied to cover the trigger points where pain was felt. For upper trapezius, the muscle was taped in the opposite direction on the cervical region in lateral flexion, slight flexion, shoulder depression and using the muscle technique with the I tape. For SCM muscle, the tape was applied on the muscle in the opposite direction on the cervical region with positioning in lateral flexion, extension and ipsilateral rotation using the muscle technique with I tape Taping was applied every 3 days and totally in 4 cycles.
Study NCT05481268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching Group
Description: In our application, 3 cycles of 20 seconds of stretches were applied to upper trapezius and SCM muscle. The patient was stretched in a relaxed and supported position and physiotherapist positioned the patient passively for stretching. For the SCM muscle, stretching was achieved in the positions of contralateral lateral flexion, ipsilateral rotation and extension. For upper trapezius, stretching was performed in flexion and lateral flexion. Stretching was performed every 3 days in 4 cycles in total.
Study NCT05481268 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Control Group patients, after the assessment by the dentist, the treatment method approved by the dentist was performed. The assessment was performed before treatment, at the end of week 1 and at the end of week 2.
Study NCT06205173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot compressing
Description: The intervention in this study will commence 15 minutes before the administration of Oxaliplatin and conclude 15 minutes after the injection. Throughout the process, the patient's local site will be checked every 15 minutes for signs of redness, abnormal sensations, and skin temperature measurement to assess potential harm caused by the applied temperature. If any adverse reactions occur, the intervention will be stopped as necessary.
Study NCT06205173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold compressing
Description: The intervention in this study will commence 15 minutes before the administration of Oxaliplatin and conclude 15 minutes after the injection. Throughout the process, the patient's local site will be checked every 15 minutes for signs of redness, abnormal sensations, and skin temperature measurement to assess potential harm caused by the applied temperature. If any adverse reactions occur, the intervention will be stopped as necessary.
Study NCT00825526 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction (MBSR) Therapy
Description: The objectives of MBSR therapy are to 1) understand their personal response to stress and 2) develop techniques to change the way these patients respond and cope with stress
Study NCT00825526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR) Therapy
Description: The objectives of MBSR therapy are to 1) understand their personal response to stress and 2) develop techniques to change the way these patients respond and cope with stress
Study NCT04385290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO
Description: Midostaurin (IMP) induction: 25 mg or 50 mg peroral BID, days 8 to 21 depending on assigned dose level~GO (IMP) induction: 3 mg/m\^2 i.v. max 4.5 mg, on day1, or on days 1, 4, or days 1, 4, 7 depending on assigned dose level~Daunorubicin (DNR, non-IMP) induction: 60 mg/m\^2/day i.v., days 1 to 3~Cytarabine (AraC, non-IMP) induction: 200 mg/m\^2/day cont. infusion, days 1 to 7
Study NCT04385290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO
Description: Midostaurin (IMP):~RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21 induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles;~GO (IMP): 3 mg/m\^2 i.v. max 4.5 mg, RP2D, 1 induction cycle only~Daunorubicin (DNR, non-IMP):~60 mg/m\^2 i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles
Study NCT04385290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO
Description: GO (IMP): 3 mg/m\^2 i.v. max 4.5 mg on days 1, 4, 7; 1 induction cycle only~Daunorubicin (DNR, non-IMP):~60 mg/m\^2/day i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles
Study NCT04385290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin
Description: Midostaurin (IMP):~RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21, induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles;~GO (IMP): 3 mg/m\^2 i.v. max 4.5 mg, RP2D, 1 induction cycle only~Daunorubicin (DNR, non-IMP):~60 mg/m\^2/day i.v., days 1 to 3 of induction cycles 1-2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles
Study NCT04385290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin
Description: Midostaurin (IMP):~RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21 induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles~Daunorubicin (DNR, non-IMP):~60 mg/m\^2/day i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles
Study NCT02172586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study NCT02172586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Study NCT02172586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Study NCT02172586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Study NCT01870674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH12852
Study NCT01870674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Study NCT01870674 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo